Evogene
Biotechnology company developing novel products for life science markets through the use of a unique CPB platform.
- biotechnology
- horizon europe
- sustainable development goals
- climate tech
- biotech and pharma
- core ai
- ai applications
- dietary supplements
- superfood
- genetics and genomics
- predictive analytics
- drug development
- genome engineering
- ai drug discovery
- techbio
- digital pharma
- organic
- techbio drug discovery
- biofuel
- crop protection
- crop
- gmo
- biopesticides
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | $5.5m | Private Placement non VC |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (11 %) | 80 % | 237 % | 51 % | (24 %) | 113 % | 44 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (2880 %) | (1424 %) | (404 %) | (226 %) | (223 %) | (88 %) | (51 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (2988 %) | (1590 %) | (423 %) | (194 %) | (259 %) | (118 %) | (82 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 2566 % | 1241 % | 368 % | 196 % | - | - | - |
Source: Company filings or news article, Equity research estimates
